Effects of metformin combined with cyproterone acetate on clinical features, endocrine and metabolism of non-obese women with polycystic ovarian syndrome

Abstract

In order to explore the effects of metformin combined with cyproterone acetate (CPA) on the clinical features, endocrine and metabolism of the patients with polycystic ovarian syndrome (P-COS), 50 cases of non-obese PCOS were randomly subjected to CPA (CPA treatment group,n=25) and CPA+metformin (n=25) treatment for 6 months. Before and after treatment the body mass index (BMI), waist: hip ratio (WHR), ovarian volume, serum gonadotrophin, androgen and sex hormone-binding globulin (SHBG) levels, and fasting lipid, glucose and insulin levels were measured. The results showed that all of the parameters in two groups were similar before treatment. After treatment for 6 months in the CPA+metformin group, BMI and WHR were significantly decreased, while insulin sensitivity was significantly decreased as compared with those before treatment. In CPA group, no significant changes were found before and after treatment. Combined use of CPA and metformin could result in the reduction of serum androstenedione and increases of serum SHBG levels as compared with the CPA treatment alone. It was concluded that combined use of CPA and metformin could improve the insulin sensitivity, and further suppress the hyperandrogenism in non-obese women with PCOS.

Keywords

cyproterone acetate / metformin / insulin resistance / polycystic ovarian syndrome

References

[1] KnochenhauerES, KeyTJ, Kahsar-MillerM, et al. . Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab, 1998, 833078-3078

[2] HacihanefiogluB, SeyisogluH, KarsidagK, et al. . Influence of insulin resistance on total rennin level in normotensive women with polycystic ovary syndrome. Fertil Steril, 2000, 73261-261

[3] TaviorA E. Insulin-lowering medications in polycystic ovary syndrome. Obstet Gynecol Cim North Am, 2000, 27583-583

[4] KorytkowskiM T, MokanM, HorwitzM J, et al. . Metabolic effects of oral contraceptives in women with polycystic ovary syndrome. J Clin Endocrinol Metab, 1995, 803327-3327

[5] RobertY, DubrulleF, GaillandreL, et al. . Ultrasound assessment of ovarian stroma hypertrophy in hyperan-drogenism and ovulation disorders: visual analysis versus computerized quantification. Fertil Steril, 1995, 64307-307

[6] DunaifA. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesia. Endocr Rev, 1997, 18(10): 774-774

[7] BailyeyC J, TurnerR C. Metformin drug therapy. N Engl J Med, 1996, 334574-574

[8] MoghettiP, CastelloR, NegriC, et al. . Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab, 2000, 85139-139

[9] Morin-PapunenL C, KoivunenR M, RuokonenA, et al. . Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril, 1998, 69691-691

[10] Ia MarcaA, EgbeT O, MorganteG, et al. . Metformin treatment reduces ovarian cytochrome P-450c17alpha response to human chorionic gonadotrophin in women with insulin resistance-related polycystic ovary syndrome. Hum Reprod, 2000, 1521-21

[11] NestlerJ E, JakubowiczD J. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. J Clin Endocrinol Metab, 1997, 824075-4075

[12] Morin-PapunenL C, VauhkonenL, KoivunenR M, et al. . Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J Clin Endocrind Metab, 2000, 853161-3161

[13] AttiaG R, RaineyW E, CarrB R. Metformin directly inhibits androgen production in human thecal cells. Fertil Steril, 2001, 76517-517

[14] DahlgrenE, LandinK, KrotkiewskiM, et al. . Effects of two antiandrogen treatments on hirsutism and insulin sensitivity in women with polycystic ovary syndrome. Hum Reprod, 1998, 132706-2706